Amarin is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. The Company has approval from the U.S. FDA to market and sell its product, Vascepaź (icosapent ethyl) capsules, as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia, which it sometimes refer to as the MARINE indication. The Company is also developing Vascepa for the treatment of patients with high TG levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels, which it refers to as mixed dyslipidemia. The Company refers to this second proposed indication for Vascepa as the ANCHOR indication.
Data provided by Mergent, Inc.